CITATIONS:
- Bhagirath A, Li Y, Somayajula D, Dadashi M, Badr S, Duan K. Cystic
fibrosis lung environment and Pseudomonas aeruginosa infection.
BMC pulmonary medicine . 5 Dec. 2016;16(1): 174.
- Kerem E, Viviani L, Zolin A, MacNeill S, Hatziagorou E, Ellemunter H,
Drevinek P, Gulmans V, Krivec U, Olesen H, ECFS Patient Registry
Steering Group. Factors associated with FEV1 decline in cystic
fibrosis: analysis of the ECFS Patient Registry. European
Respiratory Journal . 2014 Jan;43(1):125-33.
- Flume PA, Mogayzel PJ, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ,
Marshall BC, Clinical Practice Guidelines for Pulmonary Therapies
Committee. Cystic Fibrosis Pulmonary Guidelines: Treatment of
Pulmonary Exacerbations. Am J Respir Crit Care Med . 2009 Nov
1;180(9):802-8.
- Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ. The importance of
pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on
antibacterial agents. Clin Pharmacokinet . 1995
Feb;28(2):143-60.
- Kelvin H, Tan V, Mulheran M, Knox AJ, Smyth AR. Aminoglycoside
Prescribing and Surveillance in Cystic Fibrosis. Am J Respir
Crit Care Med. 2003;167: 819–823.
- Bates RD, Nahata MC, Jones JW, Mccoy K, Young G, Cox S, Barson W.
Pharmacokinetics and safety of tobramycin after once-daily
administration in patients with cystic fibrosis. Chest .
1997;112 (5): 1208– 1213.
- Coulthard KP, Peckham DG, Conway SP, Smith CA, Bell J, Turnidge J.
Therapeutic drug monitoring of once daily tobramycin in cystic
fibrosis—caution with trough concentrations. J Cyst Fibros .
2007 Apr;6(2):125-30.
- Barclay ML, Kirkpatrick CM, Begg EJ. Once daily aminoglycoside
therapy. Is it less toxic than multiple daily doses and how should it
be monitored? Clin Pharmacokinet . 1999 Feb;36(2):89-98.
- ZEMDRI® (plazomicin) injection package insert. Achaogen Inc. Revised
1/2020.
- Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL.
Prospective evaluation of the effect of an aminoglycoside dosing
regimen on rates of observed nephrotoxicity and ototoxicity.Antimicrob Agents Chemother . 1999 Jul;43(7):1549-55.
- Prescott WA, Nagel JL. Extended-Interval Once-Daily Dosing of
Aminoglycosides in Adult and Pediatric Patients with Cystic Fibrosis.Pharmacotherapy 2010;30(1):95–108.
- Khwaja A: Kidney Disease Improving Global Outcomes (KDIGO) Clinical
Practice Guideline for Acute Kidney Injury. Nephron Clin Pract.2012;120:179-184.
- VandenBussche HL, Homnick DN. Evaluation of Serum Concentrations
Achieved with an Empiric Once-Daily Tobramycin Dosage Regimen in
Children and Adults With Cystic Fibrosis. J Pediatr Pharmacol
Ther. 2012 Jan;17(1):67-77.
- Young DC, Zobell JT, Stockmann C, Waters CD, Ampofo K, Sherwin C,
Spigarelli MG. Optimization of Anti-Pseudomonal Antibiotics for Cystic
Fibrosis Pulmonary Exacerbations: V. Aminoglycosides. Pediatric
Pulmonology. 2013 Nov;48(11):1047-61.
- Zobell JT, Epps K, Kittell F, Sema C, McDade EJ, Peters SJ, Duval MA,
Pettit RS. Tobramycin and Beta-Lactam Antibiotic Use in Cystic
Fibrosis Exacerbations: A Pharmacist Approach. J Pediatr
Pharmacol Ther. 2016;21(3):239–246.
- Smyth AR, Bhatt J, Nevitt SJ. Once-daily versus multiple-daily dosing
with intravenous aminoglycosides for cystic fibrosis. Cochrane
Database of Systematic Reviews 2017 (3).
- Master V, Roberts GW, Coulthard KP, Baghurst PA, Martin A, Roberts ME,
Onishko CR, Martin AJ, Linke RJ, Holmes M, Jarvinen A, Kennedy D,
Colebatch KA, Hansman D, Parsons DW. Efficacy of once-daily tobramycin
monotherapy in acute pulmonary exacerbation of cystic fibrosis.
Pediatr Pulmonol. 2001 May;31(5):367-76.
- Whitehead A, Conway SP, Etherington C, Caldwell NA, Setchfield N,
Bogle S. Once-daily tobramycin in the treatment of adult patients with
cystic fibrosis. Eur Respir J. 2002;19:303–309.
- Smyth A, Tan KH, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D,
Prof Knox A; TOPIC Study Group. Once versus three-times daily regimens
of tobramycin treatment for pulmonary exacerbations of cystic
fibrosis–the TOPIC study: a randomised controlled trial.Lancet . 2005 Feb 12-18;365(9459):573-8.